预约演示
Merck reports rise in group net sales in fiscal 2022
2023-03-02
并购临床结果生物类似药财报上市批准
Merck’s immuno-oncology drug Bavencio generated an increase of 57.9% in organic sales. Credit: Merck KGaA, Darmstadt, Germany and/or its affiliates.
Merck has reported an increasBavencioup net sales by 12.9% to €22.23bn in fiscal 2022 against €Merck KGaA 2021.
Merckrowth in sales was driven by all regions and business sectors, particularly Life Science.
Organically, the company generated an increase of 6.4% in group sales in fiscal 2022.
Favourable foreign exchange effects of 6.1% resulted primarily from the development of the US dollar and the Chinese renminbi.
Additionally, due to the acquisition of Exelead, a biopharmaceutical contract development and manufacturing company, sales increased by 0.4%.
For fiscal 2022, Merck’s EBITDA increaseExelead4% to €6.50bn compared to €5.94bn in the prior year.
The company reporMerckn organic sales increase of 8.2% to €10.38bn in its Life Science business during the year. The EBITDA pre of Life Science grew by 14.4% to €3.76bn, reflecting a 9.7% organic rise.
Merck presented strong data in Healthcare from its 2022 pipeline about PhaLife Science for xevinapant (head and neck cancer) and evLife Scienceultiple sclerosis).
Merckg the year, the company noted that net sales of the Healthcare business increased by 1xevinapant.8head and neck cancers yearevobrutinibasmultiple sclerosis to new medicines.
Merck’s immuno-oncology drug Bavencio increased by 57.9% in organic sales.
Merckks to our broad positioning, we are confident of achieving our mid-term financial target of €25bn in sales by 2025 based purely on organic growth, with the option of further accelerating our growth through potential acquisitions and in-licensing deals.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。